Tag: discounts

DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- BiggerPockets, the premier community and resource hub for real estate investors (REIs), today announced the appointment of experienced operator and active real estate investor Eric Augustyn as Chief Executive Officer.

MAJURO, Marshall Islands, June 18, 2026 (GLOBE NEWSWIRE) --

SeerDEX has launched a Solana-based platform offering binary options and prediction markets, paired with $SEERX, a token funded in part by protocol-level buybacks.

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- GROWNSY, a baby care innovator trusted by more than 3 million households worldwide, today announced its full Amazon Prime Day 2026 strategy under the campaign theme "Baby Grows. Feeding Grows." This year's Prime Day, confirmed by Amazon as a June event across 26 countries including the United States, United Kingdom, Canada, Germany, France, Italy, and Spain, represents the earliest and most significant mid-year shopping window in the platform's history. GROWNSY is treating it as exactly that: not a routine promotion, but a pivotal moment to meet parents where they are.

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.